IFN-β (human, recombinant)

Interferon-β (IFN-β) is a cytokine and type I IFN with roles in antiviral responses and regulation of innate and adaptive immunity.¹ It is produced mainly by fibroblasts in response to viral pathogens, which are detected by a diverse repertoire of pathogen recognition receptors (PRRs).^1,2 IFN-β binds to the IFN-α/β receptor (IFNAR) and induces signal transduction through the canonical JAK/STAT signaling pathway to induce the expression of IFN-stimulated genes (ISGs), which encode proteins that have antiviral, antiproliferative, or immunomodulatory properties, leading to the induction of an antiviral state in infected and neighboring cells and inhibiting viral replication.¹ IFN-β inhibits the replication of a variety of viral pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and induces cell cycle arrest at the S phase and apoptosis in Huh7 hepatocellular carcinoma cells in vitro.^3,4 Formulations containing IFN-β have been used in the treatment of multiple sclerosis. Cayman's IFN-β (human, recombinant) protein can be used for cell-based assays. This protein consists of 166 amino acids, has a calculated molecular weight of 20 kDa, and a predicted N-terminus of Met22 after signal peptide cleavage.

WARNING This product is not for human or veterinary use.

1. Ivashkiv, L.B., and Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14(1), 36-49 (2014).

2. Haller, O., Kochs, G., and Weber, F. The interferon response circuit: Induction and suppression by pathogenic viruses. Virology 344(1), 119-130 (2006).

3. Mantlo, E., Bukreyeva, N., Maruyama, J., et al. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 179, 104811 (2020).

4. Murata, M., Nabeshima, S., Kikuchi, K., et al. A comparison of the antitumor effects of interferon-α and β on human hepatocellular carcinoma cell lines. Cytokine 33(3), 121-128 (2006).